Surface Oncology Resets Portfolio Priorities, Extends Cash Runway Through 2021
Significantly reduces scope of its CD47 program, SRF231 Accelerates IND filing for SRF388 (IL-27) into Q4 2019 IND filing for SRF617 (CD39) remains on track for Q4 2019 CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a …